STOCK TITAN

CeriBell (CBLL) 10-K Filings

CBLL NASDAQ

Here are the 10-K annual reports from CeriBell, Inc. (CBLL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow CBLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBLL filings page.

Rhea-AI Summary

CeriBell, Inc. is a medical technology company focused on point-of-care EEG for critically ill patients, using AI-powered algorithms to detect seizures, delirium and other serious neurological conditions. Its Ceribell System combines disposable headbands or headcaps, a pocket-sized recorder and a cloud portal for real-time monitoring.

As of December 31, 2025, the system had been adopted by more than 600 U.S. hospitals, targeting a U.S. addressable market it estimates at over $3.5 billion when including seizures and delirium. In 2025 CeriBell generated $89.1 million in revenue, up from $65.4 million in 2024, with a gross margin of 88% and a net loss of $53.4 million.

Growth is supported by expanding clinical indications: FDA 510(k) clearance for its Clarity algorithm to diagnose electrographic status epilepticus in adults and for delirium monitoring, plus Breakthrough Device Designation for an in‑development large vessel occlusion stroke detection solution. The company relies on recurring revenue from single-use Wearables and subscriptions to its software and hardware platform.